Abstract 2832: Targeted genomic landscape of metastases compared to primary tumors in non-small-cell lung cancer

Abstract

Abstract The genomic landscape of primary non-small-cell lung cancer (NSCLC) has been well described. However, little is known about cohort genomic alterations (GA) landscape in NSCLC metastases, and how it compares with primary tumors in general. The genomic landscape of metastases may be important for clinical treatment and prognosis. In this retrospective study, 37 cases of surgically resected NSCLC were studied, of which 19 were non-metastatic NSCLC and 18 were metastatic NSCLC. Sixty formalin-fixed paraffin-embedded (FFPE) tissue samples from 37 NSCLC patients, including the primary lesion of non-metastatic NSCLC (Group A, N =19), the primary lesion of metastatic NSCLC (Group B, N =18), and lymph node lesions (Group C, N =23), were included to detect somatic mutations using a 1021-gene panel by next-generation sequencing (NGS). In this study, twenty-nine patients (78.4%) were male. Nineteen patients with lung adenocarcinoma (LUAD) and 18 with lung squamous cell carcinoma (LUSC) were included. In addition, there were significant differences between Groups A and B in stage T and stage N (P < 0.0001). Overall, EGFR (33.3% vs 15.8%) and TERT (16.7% vs 5.2%) were numerically more frequently mutated in metastases, but differences were not statistically significant. Moreover, we found that ARID1A may be closely related to metastasis in LUSC (P = 0.029). These data support the theory that primary and metastatic NSCLC encompass a uniform distribution of common genomic alterations tested by next-generation sequencing targeted panels. While ARID1A may be closely related to metastasis in LUSC. Citation Format: Bing Chen, Gaochao Dong, Yingkuan Liang, Te Zhang, Junling Zhang, Shiqing Chen, Feng Jiang, Lin Xu. Targeted genomic landscape of metastases compared to primary tumors in non-small-cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2832.